| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.097 | 0.009 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.42 | 0.01 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.38 | 0.02 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |